10 studies found for:    SAR236553 | Sanofi [Lead] | Regeneron | Phase 3
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: matching placebo alirocumab SAR236553 (REGN727);   Drug: Ezetimibe;   Other: matching placebo for Ezetimibe
2 Active, not recruiting Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: matching placebo alirocumab SAR236553 (REGN727);   Drug: Ezetimibe;   Drug: matching placebo for Ezetimibe
3 Active, not recruiting Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY High FH)
Condition: Hypercholesterolaemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: placebo
4 Active, not recruiting Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
5 Active, not recruiting Long-term Safety and Tolerability of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Condition: Hypercholesterolemia
Interventions: Other: placebo;   Drug: alirocumab SAR236553 (REGN727)
6 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
7 Completed Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY Combo I)
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Other: Placebo
8 Active, not recruiting Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727) Dose Regimen A;   Drug: alirocumab SAR236553 (REGN727) Dose Regimen B;   Drug: alirocumab matching placebo
9 Recruiting Open Label Study of Long Term Safety Evaluation of Alirocumab
Condition: Hypercholesterolemia
Intervention: Drug: Alirocumab SAR236553 (REGN727)
10 Active, not recruiting Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Other: placebo;   Drug: alirocumab SAR236553 (REGN727);   Drug: pravastatin;   Drug: simvastatin;   Drug: fluvastatin;   Drug: atorvastatin;   Drug: pitavastatin;   Drug: rosuvastatin

Indicates status has not been verified in more than two years